<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <Volume-Issue>Volume 15, Issue 01,2023 </Volume-Issue>
      <ArticleTitle>Overview of amyotrophic lateral sclerosis and medications for disease progression</ArticleTitle>
      <Abstract>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects the nerve cells responsible for controlling voluntary muscle movement. The progression of ALS varies, but generally follows a predictable pattern. There is no cure for ALS, and treatment is focused on managing symptoms and maximizing quality of life. Medications such as riluzole and edaravone are commonly prescribed to manage symptoms and slow the disease progression. Riluzole works by reducing the release of glutamate, a neurotransmitter that can damage motor neurons, modulating voltage-gated sodium channels, and stabilizing intracellular calcium levels. Clinical trials have demonstrated that riluzole can help slow the progression of ALS, though it does not cure the disease. It is important to note that riluzole is not effective for all patients with ALS, and its benefits are modest. Therefore, it is important to discuss the potential benefits and risks of riluzole with a health-care provider before starting treatment.</Abstract>
      <Keywords>Amyotrophic lateral sclerosis, Medications, Neurodegenerative disease</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=14650&amp;title=Overview of amyotrophic lateral sclerosis and medications for disease progression</Abstract>
        <References>1. Alam MM, Minj E, Yadav RK, Mehan S. Neuroprotective potential of adenyl cyclase/cAMP/CREB and mitochondrial CoQ10 activator in amyotrophic lateral sclerosis rats. Curr Bioact Compd 2021;17:53-69.&#13;
2. Yadav KY, Mehan S. Targeting abnormal Nrf2/HO-1 signaling in amyotrophic lateral sclerosis: Current insights on drug targets and influences on neurological disorders. Curr Mol Med 2021;21:630-44.&#13;
3. Zhou Q, Wang Y, Zhang J, Shao Y, Li S, Wang Y, et al. Fingerprint analysis of Huolingshengji Formula and its neuroprotective effects in SOD1G93A mouse model of amyotrophic lateral sclerosis. Sci Rep 2018;8:1668.&#13;
4. Corcia P, Beltran S, Bakkouche SE, Couratier P. Therapeutic news in ALS. Rev Neurol (Paris) 2021;177:544-9.&#13;
5. Witzel S, Maier A, Steinbach R, Grosskreutz J, Koch JC, Sarikidi A, et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol 2022;79:121-30.&#13;
6. Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 2019;39:733-48.&#13;
7. Bhandari R, Kuhad A, Kuhad A. Edaravone: A new hope for deadly amyotrophic lateral sclerosis. Drugs Today (Barc) 2018;54:349-60.&#13;
8. Yoshino H. Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother 2019;19:185-93.&#13;
9. Rokade AV, Yelne P, Giri A. Riluzole and edavarone: The hope against amyotrophic lateral sclerosis. Cureus 2022;14:e30035.&#13;
10. Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin Pharmacother 2017;18:735-8.&#13;
11. Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP-43 misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci 2019;12:25.&#13;
12. Gelon PA, Dutchak PA, Sephton CF. Synaptic dysfunction in ALS and FTD: Anatomical and molecular changes provide insights into mechanisms of disease. Front Mol Neurosci 2022;15:1000183.</References>